AZD 1981
Alternative Names: AZD-1981Latest Information Update: 05 Nov 2023
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Johns Hopkins University
- Class Antiasthmatics
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic urticaria
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 02 Aug 2019 No development reported - Phase-II for Chronic-urticaria (Treatment-resistant) in USA (PO) (NCT02031679)
- 09 Mar 2016 AZD 1981 is still in phase II trials for Chronic-urticaria in USA (PO)
- 07 Mar 2016 Johns Hopkins University in collaboration with AstraZeneca completes a phase II trial in Urticaria in USA (PO) (NCT02031679)